PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 per share (PMVP)

Q: What does CUSIP 69353Y103 represent in this 13F holders report?

CUSIP 69353Y103 is the security identifier for PMVP - PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 per share used to aggregate holder disclosures.

Q: How many institutions held PMVP - PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 per share in Q1 2025?

54 institutional investors reported PMVP - PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 per share for Q1 2025. Use the holders table for investor-level position and value details.

CUSIP: 69353Y103

Q1 2025 13F Holders as of 31 Mar 2025

Type / Class: Equity / Common stock, par value $0.00001 per share
Shares outstanding: 53,320,277
Total 13F shares: 37,320,031
Share change: -1,639,060
Total reported value: $40,676,123
Put/Call ratio: 5.9%
Price per share: $1.09
Number of holders: 54
Value change: -$2,281,115
Number of buys: 10
Number of sells: 47

Quarterly Holders Quick Answers

What is CUSIP 69353Y103?
CUSIP 69353Y103 identifies PMVP - PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q2 2025
Previous quarter: Q4 2024

Recent filing periods for CUSIP 69353Y103:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of PMVP - PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
INTERWEST PARTNERS X LP	3/4/5	10%+ Owner	— class O/S missing	4,502,480	$10,040,531	—	13 Jul 2021	3/4/5
ORBIMED ADVISORS LLC	13F	Company	12%	6,475,291	$9,777,689	—	31 Dec 2024	13F
Sio Capital Management, LLC	13F	Company	6.7%	3,572,167	$5,393,972	—	31 Dec 2024	13F
ArrowMark Colorado Holdings LLC	13F	Company	6.6%	3,508,451	$5,297,761	—	31 Dec 2024	13F
BML Capital Management, LLC	13F	Company	6.5%	3,466,684	$5,234,693	—	31 Dec 2024	13F
Euclidean Capital LLC	13F 3/4/5	Company · 10%+ Owner	4.9%	2,627,643	$3,967,741	—	31 Dec 2024	13F 3/4/5
ALKEON CAPITAL MANAGEMENT LLC	13F	Company	4.4%	2,343,731	$3,539,033	—	31 Dec 2024	13F
VANGUARD GROUP INC	13F	Company	4%	2,143,102	$3,236,084	—	31 Dec 2024	13F
PFM Health Sciences, LP	13F	Company	3.9%	2,079,245	$3,139,660	—	31 Dec 2024	13F
ACADIAN ASSET MANAGEMENT LLC	13F	Company	3.9%	2,078,866	$3,136,000	—	31 Dec 2024	13F
Thilo Schroeder	3/4/5	Director	— class O/S missing	1,101,283	$2,455,861	—	06 Oct 2021	3/4/5
BlackRock, Inc.	13F	Company	2.2%	1,146,484	$1,731,190	—	31 Dec 2024	13F
D. E. Shaw & Co., Inc.	13F	Company	1.9%	1,024,288	$1,546,675	—	31 Dec 2024	13F
TWO SIGMA ADVISERS, LP	13F	Company	1.3%	714,600	$1,079,046	—	31 Dec 2024	13F
JACOBS LEVY EQUITY MANAGEMENT, INC	13F	Company	1%	539,893	$815,238	—	31 Dec 2024	13F
Stonepine Capital Management, LLC	13F	Company	1%	535,805	$809,066	—	31 Dec 2024	13F
CITIGROUP INC	13F	Company	0.97%	514,911	$777,516	—	31 Dec 2024	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.95%	506,986	$765,549	—	31 Dec 2024	13F
Aldebaran Capital, LLC	13F	Company	0.94%	502,190	$758,307	—	31 Dec 2024	13F
Peapod Lane Capital LLC	13F	Company	0.84%	445,744	$673,073	—	31 Dec 2024	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.79%	421,710	$636,963	—	31 Dec 2024	13F
M&T BANK CORP	13F	Company	0.75%	399,548	$603,659	—	31 Dec 2024	13F
Connor, Clark & Lunn Investment Management Ltd.	13F	Company	0.7%	370,920	$560,089	—	31 Dec 2024	13F
BAKER BROS. ADVISORS LP	13F	Company	0.6%	322,024	$486,256	—	31 Dec 2024	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.6%	318,020	$480,210	—	31 Dec 2024	13F
UBS Group AG	13F	Company	0.52%	275,464	$415,951	—	31 Dec 2024	13F
RBF Capital, LLC	13F	Company	0.46%	245,561	$379,967	—	31 Dec 2024	13F
BRIDGEWAY CAPITAL MANAGEMENT, LLC	13F	Company	0.38%	202,100	$305,171	—	31 Dec 2024	13F
STATE STREET CORP	13F	Company	0.3%	157,578	$237,943	—	31 Dec 2024	13F
Shay Capital LLC	13F	Company	0.29%	156,451	$236,241	—	31 Dec 2024	13F
Assenagon Asset Management S.A.	13F	Company	0.29%	153,701	$232,089	—	31 Dec 2024	13F
EVOKE WEALTH, LLC	13F	Company	0.25%	133,122	$201,014	—	31 Dec 2024	13F
Walleye Capital LLC	13F	Company	0.24%	127,626	$192,715	—	31 Dec 2024	13F
DIMENSIONAL FUND ADVISORS LP	13F	Company	0.24%	126,004	$190,238	—	31 Dec 2024	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.23%	121,245	$183,080	—	31 Dec 2024	13F
CITADEL ADVISORS LLC	13F	Company	0.2%	107,888	$162,911	—	31 Dec 2024	13F
NORTHERN TRUST CORP	13F	Company	0.2%	107,340	$162,083	—	31 Dec 2024	13F
ADAR1 Capital Management, LLC	13F	Company	0.19%	101,008	$152,522	—	31 Dec 2024	13F
PANAGORA ASSET MANAGEMENT INC	13F	Company	0.17%	89,631	$135,343	—	31 Dec 2024	13F
Squarepoint Ops LLC	13F	Company	0.14%	73,015	$110,253	—	31 Dec 2024	13F
PNC FINANCIAL SERVICES GROUP, INC.	13F	Company	0.13%	69,113	$104,361	—	31 Dec 2024	13F
Leila Alland	3/4/5	Chief Medical Officer	— class O/S missing	45,909	$102,377	—	15 Sep 2023	3/4/5
Marquette Asset Management, LLC	13F	Company	0.12%	64,009	$96,654	—	31 Dec 2024	13F
JANE STREET GROUP, LLC	13F	Company	0.09%	49,870	$75,304	—	31 Dec 2024	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.08%	44,568	$67,297	—	31 Dec 2024	13F
MORGAN STANLEY	13F	Company	0.08%	41,763	$63,062	—	31 Dec 2024	13F
ROYAL BANK OF CANADA	13F	Company	0.08%	40,384	$61,000	—	31 Dec 2024	13F
HSBC HOLDINGS PLC	13F	Company	0.07%	39,080	$58,034	—	31 Dec 2024	13F
Schonfeld Strategic Advisors LLC	13F	Company	0.07%	35,200	$53,152	—	31 Dec 2024	13F
Velan Capital Investment Management LP	13F	Company	0.07%	35,000	$52,850	—	31 Dec 2024	13F

Institutional Holders of PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 per share (PMVP) as of Q1 2025

As of 31 Mar 2025, PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 per share (PMVP) was held by 54 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 37,320,031 shares. The largest 10 holders included ORBIMED ADVISORS LLC, BML Capital Management, LLC, Sio Capital Management, LLC, ArrowMark Colorado Holdings LLC, PFM Health Sciences, LP, Euclidean Capital LLC, ALKEON CAPITAL MANAGEMENT LLC, VANGUARD GROUP INC, ACADIAN ASSET MANAGEMENT LLC, and BlackRock, Inc.. This page lists 54 institutional shareholders reporting positions in this security for the Q1 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q1 2025 vs Q4 2024 Across Filers

Q4 2024 holders

Q1 2025 holders

Holder diff

-16

Investor	Q4 2024 Shares	Q1 2025 Shares	Share Diff	Share Chg %	Q4 2024 Value $	Q1 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.